BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17050864)

  • 1. Did targeted therapy fail cyclooxygenase too?
    Csiki I; Johnson DH
    J Clin Oncol; 2006 Oct; 24(30):4798-800. PubMed ID: 17050864
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cyclooxygenase 2 inhibitors and lung carcinoma].
    Spano JP; Chouahnia K; Morère JF
    Bull Cancer; 2004 May; 91 Suppl 2():S109-12. PubMed ID: 15899634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.
    De Ruysscher D; Bussink J; Rodrigus P; Kessels A; Dirx M; Houben R; Wanders R
    Radiother Oncol; 2007 Jul; 84(1):23-5. PubMed ID: 17532073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
    Backhus LM; Petasis NA; Uddin J; Schönthal AH; Bart RD; Lin Y; Starnes VA; Bremner RM
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1406-12. PubMed ID: 16256796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxibs and cardiovascular risk.
    Allen MJ; McLean-Veysey P; Fleming I
    CMAJ; 2005 Oct; 173(8):853. PubMed ID: 16217098
    [No Abstract]   [Full Text] [Related]  

  • 6. COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?
    Bannwarth B
    Expert Opin Drug Saf; 2006 Jan; 5(1):1-2; author reply 1-2. PubMed ID: 16370948
    [No Abstract]   [Full Text] [Related]  

  • 7. Balancing the risks and benefits of celecoxib.
    Caldwell B; Beasley R; Weatherall M; Metcalfe S
    Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
    [No Abstract]   [Full Text] [Related]  

  • 8. Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications.
    Gradilone A; Pulcinelli FM; Lotti LV; Martino S; Mattiello T; Frati L; Aglianò AM; Gazzaniga P
    J Clin Oncol; 2007 Sep; 25(27):4318-20; author reply 4320. PubMed ID: 17878487
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in treatment for non-small cell lung cancer.
    Price KA; Jett JR
    Int J Tuberc Lung Dis; 2010 Jul; 14(7):792-4. PubMed ID: 20550759
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain.
    Reuben SS
    Acta Anaesthesiol Scand; 2005 Mar; 49(3):424; author reply 425. PubMed ID: 15752415
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trials. Halt of Celebrex study threatens drug's future, other trials.
    Couzin J
    Science; 2004 Dec; 306(5705):2170. PubMed ID: 15618492
    [No Abstract]   [Full Text] [Related]  

  • 12. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
    Hawk E; Viner JL
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
    Backlund MG; Amann JM; Johnson DH
    J Clin Oncol; 2008 Feb; 26(6):825-7. PubMed ID: 18281650
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
    Couzin J
    Science; 2005 Dec; 310(5756):1890-1. PubMed ID: 16373546
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
    Besse B; Le Chevalier T
    J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
    [No Abstract]   [Full Text] [Related]  

  • 16. Celecoxib and radiation therapy in non-small-cell lung cancer.
    Gore E
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):10-4. PubMed ID: 15685827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.
    Prescrire Int; 2008 Jun; 17(95):106. PubMed ID: 18627117
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting COX-2/PG-E2 with a COX-2 inhibitor in combination with chemotherapy for non-small cell lung cancer: are we ready for phase III?
    Aisner J
    Cancer J; 2005; 11(3):201-3. PubMed ID: 16053662
    [No Abstract]   [Full Text] [Related]  

  • 19. Celecoxib-induced deep-vein thrombosis.
    Chan AL
    Ann Pharmacother; 2005 Jun; 39(6):1138. PubMed ID: 15840730
    [No Abstract]   [Full Text] [Related]  

  • 20. The pain game.
    Wadman M
    Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.